Catalent (CTLT)
(Real Time Quote from BATS)
$56.66 USD
+1.84 (3.36%)
Updated Jun 21, 2024 11:26 AM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Brokerage Reports
Catalent, Inc. [CTLT]
Reports for Purchase
Showing records 81 - 100 ( 216 total )
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Early FY23 Guidance Shows Path Beyond COVID
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Bioproduction: Catalent''s $350M Indiana Expansion Signals Growth
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
2022 Life Sciences and MedTech Conference: Day 2 Takeaways
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Growth Exceeds; Nuggets Around COVID, 483, Cell Therapy Outlook; Read-Throughs
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Goldilocks Ignored - JPM Week and Implications for Coverage List
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Transformational Year Validating Higher Industry Growth
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Company: Catalent, Inc.
Industry: Medical - Drugs
Wegovy for Novo Nordisk Appears Immaterial and No Vaccine/ Therapy Implications
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalent, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department